Company Directory - American Society of Clinical Oncology
Company Details - American Society of Clinical Oncology
American Society of Clinical Oncology
WebsiteA leading professional organization dedicated to improving cancer care and supporting cancer research and education globally. The organization focuses on advancing the science and practice of oncology through various initiatives, including research funding, educational programs, and advocacy efforts.
CCI Score
CCI Score: American Society of Clinical Oncology
44.59
4.43%
Latest Event
ASCO Study Links Anti-Inflammatory Diet to Improved Colon Cancer Survival
A new study from the American Society of Clinical Oncology reports that incorporating anti-inflammatory foods may boost survival rates among advanced colon cancer patients, reflecting the organization’s commitment to advancing cancer care through robust research and advocacy for public health improvements.
Take Action
So what can you do? Support ASCO by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
DISSENTER
American Society of Clinical Oncology is currently rated as a Dissenter.
Latest Events
- JUN062025
A new study from the American Society of Clinical Oncology reports that incorporating anti-inflammatory foods may boost survival rates among advanced colon cancer patients, reflecting the organization’s commitment to advancing cancer care through robust research and advocacy for public health improvements.
- MAY122025
ASCO has mobilized oncology professionals to educate lawmakers on the need for robust federal funding for cancer research, improved patient access, and Medicaid protections, while also focusing on improving physician wellness and reducing administrative overload based on member feedback.
+75
Political Contributions and Lobbying Efforts
June 6
ASCO actively organized hundreds of professionals to engage with policymakers on issues such as federal funding for cancer research and securing Medicaid protections. This advocacy work supports progressive policy objectives, countering austerity measures and authoritarian cuts.
ASCO Driving Member Priorities: Legislative Advocacy and Workplace Issues
+60
Labor Relations and Human Rights Practices
June 6
In addition to its legislative advocacy, ASCO is taking concrete steps to address physician burnout and administrative overload, thereby promoting better work conditions and supporting the rights and well-being of healthcare professionals.
ASCO Driving Member Priorities: Legislative Advocacy and Workplace Issues
- JAN032025
On January 3, 2025, ASCO leveraged its long-standing relationships with Members of Congress to advocate for policies aimed at increasing access to high-quality, equitable cancer care, reinforcing progressive efforts towards health equity.
+60
Public and Political Behavior
June 6
ASCO's active engagement with new lawmakers to advocate for progressive cancer care policies demonstrates strong public and political behavior. This proactive stance in promoting equitable access to care is a positive, anti-authoritarian action that benefits marginalized communities by pushing for systemic improvements in healthcare access.
Advocating for Cancer Care, Research Priorities in New Congress ...
- JAN012025ASCO Lobbying Activity 2025
-28.74
The American Society of Clinical Oncology spent $250,000 on lobbying efforts in 2025, as reported by OpenSecrets. This expenditure highlights the organization's engagement in influencing policymaking processes.
-30
Political Contributions and Lobbying Efforts
June 6
ASCO's allocation of $250,000 towards lobbying in 2025 raises concerns about the organization's role in influencing policy decisions. From an anti-fascist perspective, such political expenditures can contribute to the concentration of power among elites, potentially undermining democratic accountability and reinforcing authoritarian influence.
- MAR142024
ASCO released a policy statement advocating for global equity in clinical trials, emphasizing diversity, equity, and inclusion in cancer research to ensure fair representation of marginalized populations, particularly in low- and middle-income countries.
+70
Public and Political Behavior
June 6
ASCO’s policy statement calls for greater equity in clinical trials, promoting diversity and inclusion in research. This initiative supports progressive, anti-authoritarian practices by addressing longstanding disparities in global health, particularly benefiting marginalized populations in low- and middle-income countries.
- JAN012024
The American Society of Clinical Oncology spent $950,000 on lobbying activities during the 2024 cycle, as reported by OpenSecrets. This expenditure is intended to influence policy decisions related to cancer research funding and healthcare policy.
+20
Political Contributions and Lobbying Efforts
June 6
Spending $950,000 on lobbying suggests that ASCO is actively engaging in the political process. Given its focus on cancer care and research funding, the lobbying effort is likely aimed at promoting policies that enhance public health and support marginalized patient communities. While political lobbying can sometimes be associated with undue corporate influence, in this case the effort appears to support evidence-based policy and improved healthcare outcomes, aligning with anti-authoritarian goals.
- MAY172023
An ASCO member, Association Chair Lori J. Pierce, testified before Congress urging a significant increase in federal funding for cancer research agencies including NIH, NCI, and ARPA-H. The testimony, submitted on May 17, 2023, emphasized bipartisan support for robust biomedical research, aligning with progressive efforts to bolster public health research infrastructure.
+70
Executive Political Engagement
June 6
The testimony by ASCO's Association Chair demonstrates proactive engagement in political processes to secure increased federal funding for cancer research. This act of executive political engagement supports progressive public health priorities and underscores the organization's commitment to advancing scientific research, which is viewed as an anti-authoritarian and socially beneficial effort.
- JAN012023
The American Society of Clinical Oncology is actively engaged in lobbying efforts on a range of healthcare-related bills, including acts addressing Medicare telehealth privacy, access to lifesaving drugs, cancer survivorship, and pharmaceutical supply chain vulnerabilities. These activities indicate the organization's effort to influence legislative outcomes in support of enhanced cancer care and patient access.
+50
Political Contributions and Lobbying Efforts
June 6
ASCO’s active lobbying on a portfolio of healthcare-focused legislation suggests a commitment to advancing policies that can improve access to care, drug affordability, and patient protections. These efforts contribute positively to public policy by potentially countering restrictive or authoritarian health policies, and align with progressive, anti-fascist objectives.
- DEC162021
ASCO, in collaboration with other leading healthcare organizations, released a series of policy and marketplace recommendations aimed at addressing critical challenges in the United States drug supply chain exacerbated by the COVID-19 pandemic. The recommendations focus on enhancing supply chain resilience, adopting advanced manufacturing technologies, and improving the effectiveness of national stockpiles to ensure a safe and uninterrupted supply of quality medications.
+70
Public and Political Behavior
June 6
ASCO's participation in issuing comprehensive policy recommendations to address drug supply chain vulnerabilities reflects a proactive stance in influencing public policy for improved healthcare access and safety. This action supports progressive regulatory approaches to protect public health and ensure equitable access to essential medications, aligning with anti-authoritarian and anti-fascist values.
Alternatives
Geneva, Switzerland
66.66
London, United Kingdom
59.52
Corporation
47.37
Corporation
45.72
Corporation
44.55
Corporation
34.42
Corporation
-36.91
Washington, United States
69.04
Germany
65.50
Geneva, Switzerland
57.01
Industries
- 541720
- Research and Development in the Social Sciences and Humanities
- 621111
- Offices of Physicians (except Mental Health Specialists)
- 813920
- Professional Organizations